C4 Therapeutics
c4therapeutics.com
Actively hiring
Oncology Therapeutics
Drug Discovery
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
C4 Therapeutics Director Kenneth Carl Anderson Acquires 3,662 Shares Instead of Cash Compensation
Read more
Report
C4 Therapeutics Reports New Cemsidomide Myeloma Data
Detailed price information for C4 Therapeutics Inc (CCCC-Q) from The Globe and Mail including charting and trades.
Read more
Report
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action Biomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elr
Read more
Report
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the...
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedi...
Read more
Report
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
Read more
Report
Report
Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?
C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays lowered the firm's price target on C4 Therapeutics to $5 from $10, while maintaining an Overweight rating on the shares. The
Read more
Report
Salary insights
Compensation ranges based on this company's open jobs
Median
$216k
Typical range
$141k – $254k
Open positions
4
4
Jobs
Middle
25%
Principal
50%
Architect
25%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Middle | 1 | $141k | $141k |
| Principal | 2 | $226k | $198k – $254k |
| Architect | 1 | $233k | $233k |
Highest paying role
Principal Scientist, Formulations
$254k
Normalized to USD per year
People
Marc Cohen
Executive Officer, Director
Jason Fisherman
Executive Officer, Director
Miles Stuchin
Director
William Scalzulli
Director
Kenneth Anderson
Director
Malcolm Salter
Director
Bruce Downey
Director
Jay Eastman
Director
Alain Cohen
Director
Elena Prokupets
Director
Bihua Chen
Director
Ronald Kaiser
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
27/100
Slowing
Open positions
4
0 opened / 0 closed in 30 days
Median time-to-fill
26 days
faster than 47% of the market
ATS activity
Every ~4 hours
Today
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
60% ▲
Finance
20% ▲
HR
20% ▲
Actively hiring for Science & Research (+3 in 30 days)
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
1
Busiest office
Watertown
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cambridge
United States
HQ
Watertown
United States
Corporate office
490 Arsenal Way, Suite 120
4 open roles 5 posted in 90 days 50% engineering 200-500 est. staff $207k Avg Salary
hires for Science & Research, Finance, HR
490 Arsenal Way, Suite 120, Watertown, MA 02472
Financials
Total raised
$70.3M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2015 | $70.3M | Details |